National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved July 1997

Specific Treatments:

Parkinson's Disease

Therapeutic Areas

General Information

Pramipexole was cleared for marketing in the U.S. on July 10, 1997. This is the first new anti-Parkinsonian drug to hit the market in the past six years. Pramipexole can be used to treat all stages of Parkinson's disease. Pramipexole, when given concomitantly with levodopa, improves patients with advanced Parkinson's disease and levodopa-induced motor fluctuation.